Vol 2 (February 25, 2024): AME Clinical Trials Review

Combining neoadjuvant and adjuvant immunotherapy breathes more life into the growing body of lung cancer treatment paradigms

The third-generation EGFR TKI osimertinib could be a promising neoadjuvant therapy in patients with resectable EGFR-mutant NSCLC

Commentary: is segmentectomy curative in patients with early-stage ground glass opacity predominant non-small cell lung cancer?

Changing the way we treat KRAS G12C non-small cell lung cancers

How should we combine radiotherapy and immunotherapy in advanced non-small cell lung cancer?

The role of confirmatory mediastinoscopy after negative endosonography: is it truly necessary?

A long-awaited novel approach for the treatment of undetectable small-sized lung cancers in thoracoscopic surgery

Real-world evidence for immune checkpoint inhibitors in extensive-stage small cell lung cancer

CheckMate 817: expanding the pool of patients eligible for immune checkpoint inhibitor therapy in advanced non-small cell lung cancer

Should we change strategy for adjuvant therapy according to surgery type in stage II–IIIA non-small cell lung cancer?